The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.

In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.

将医学上的新发现转化为临床常规从来都不是一件容易的事。在上个世纪下半叶，由于化学、生物化学和药理学的进步，我们看到了大量药物和设备的开发和应用，这些药物和设备旨在治疗症状、阻断不必要的途径，并在传染病的情况下对抗导致疾病的微生物。然而，今天，我们正面临着病理和疾病治疗方法的巨大变化。事实上，现在和未来十年的挑战是完全恢复患病生物体的生理状态，并在组织和器官受到严重影响以至于治疗不能局限于抑制症状或修复损伤时完全再生组织和器官。这得益于基础细胞和分子生物学的重大发展，包括干细胞科学、生长因子传递、基因分离和转染，生物工程和纳米技术的进步，包括新生物材料的开发、生物制造技术和生物反应器的使用，以及诊断工具和细胞、组织和器官成像的巨大改进。

在当今世界，加强多学科专家之间的交流，促进联合项目以及科学家、工程师、行业人士、监管机构和医生之间的密切合作，是成功开发和临床应用新生物疗法或创新设备（涉及生物材料、细胞和/或生物活性分子的集体使用）的绝对要求。“生物工程和生物技术前沿”希望成为参与这一过程的所有人的一个论坛，弥合基础科学发现与其临床应用之间经常存在的差距。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映Chemical Engineering-Bioengineering领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为4.3，平均审稿速度为 12 Weeks ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。